Holen Sie sich die Stockscreener-App
0.6801
2.82%
-0.0197
Handel nachbörslich:
.68
-0.000100
-0.01%
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Significant EPS Beat Despite Zero RevenueHigh Interest Stocks - Newser
KTTA Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock SlipsEarnings Seasonality - Newser
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained - TipRanks
Pasithea Therapeutics Corp.Common Stock (NQ: KTTA - The Chronicle-Journal
Pasithea Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea Therapeutics Corp. 1Q 2026: Net loss $(2.87M), EPS $(0.12) — 10-Q Summary - TradingView
Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pasithea Therapeutics (NASDAQ: KTTA) ramps PAS-004 R&D on $50M cash base - Stock Titan
Ameriprise (KTTA) reports 1.35M-share, 5.4% stake in Pasithea Therapeutics - Stock Titan
TradingKey - TradingKey
Pasithea Therapeutics appoints chief medical officer - MSN
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Pasithea Therapeutics (KTTA) CEO awarded 1.76M stock options at $0.841 - Stock Titan
Pasithea (NASDAQ: KTTA) grants director 152,783 options at $0.841 strike - Stock Titan
Pasithea Therapeutics (KTTA) director receives 152,783 stock options grant - Stock Titan
Pasithea Therapeutics (KTTA) CFO receives 1.13M-share stock option grant - Stock Titan
[Form 4] Pasithea Therapeutics Corp. Insider Trading Activity - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) grants director Emer Leahy 152,783 options - Stock Titan
Pasithea (KTTA) director receives 152,783 stock options at $0.841 - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) names Chief Medical Officer as reporting insider on Form 3 - Stock Titan
Pasithea Therapeutics Appoints Dr. Kartik Krishnan as Chief Medical Officer to Advance PAS-004 MEK Inhibitor for NF1 and Rare Diseases 12 - Minichart
8-K: Current report - Moomoo
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives - TipRanks
New CMO and large option grants at Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - Investing News Network
Pasithea names Kartik Krishnan as chief medical officer By Investing.com - Investing.com South Africa
Pasithea Therapeutics Appoints Kartik Krishnan as Chief Medical Officer - citybiz
Pasithea names Kartik Krishnan as chief medical officer - Investing.com
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Funicular Funds (KTTA) reports 1.84M shares, 7.4% stake in Pasithea (KTTA) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Pasithea Therapeutics Corp (KTTA) - The Globe and Mail
KTTA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 - Investing News Network
FDA grants rare pediatric disease status to Pasithea’s PAS-004 By Investing.com - Investing.com South Africa
FDA grants rare pediatric disease status to Pasithea’s PAS-004 - Investing.com
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) - ChartMill
Pasithea Therapeutics (KTTA) Stock Employment Data (Grinds Lower) 2026-04-20Gap Up Stocks - Newser
Coastlands Capital reveals KTTA (NASDAQ: KTTA) stake in shares and pre-funded warrants - Stock Titan
Form 3Initial statement of beneficial ownership of securities - ADVFN
Can Pasithea Therapeutics Corp grow without external funding2026 Momentum Check & Verified Short-Term Plans - baoquankhu1.vn
Should you buy the dip on Pasithea Therapeutics Corp2026 Weekly Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Loss Report: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantPortfolio Gains Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Wrap: Can Pasithea Therapeutics Corp grow without external funding2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Is Pasithea Therapeutics (KTTA) Stock Good for Passive Investors | Price at $0.76, Down 0.52%Growth ETF - Newser
Opaleye/James Silverman hold 2.49M shares of Pasithea (KTTA) in Schedule 13G - Stock Titan
Aug Opening: Whats the beta of Pasithea Therapeutics Corp stockTreasury Yields & Daily Chart Pattern Signals - baoquankhu1.vn
Buyback Watch: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Pasithea Therapeutics Corp reports results for the quarter ended December 31Earnings Summary - TradingView
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):